Valuation : GlaxoSmithKline Pharmaceuticals Limited

Market Cap 50TCr 523.33Cr 449.96Cr 423.32Cr 386.31Cr 720.93Cr 724.66Cr 5.02TCr 1.94TCr 25TCr 1.97TCr 1.92TCr 81TCr P/E 2027 *
42.6x
P/E 2028 * 37x
Enterprise Value 50TCr 523.33Cr 449.96Cr 423.32Cr 386.31Cr 720.93Cr 724.66Cr 5.02TCr 1.94TCr 25TCr 1.97TCr 1.92TCr 81TCr EV / Sales 2027 *
11.7x
EV / Sales 2028 * 10.5x
Free-Float
-
Yield 2027 *
1.01%
Yield 2028 * 1.01%

Last Transcript : GlaxoSmithKline Pharmaceuticals Limited

1 day-1.00%
1 week-2.27%
Current month-4.00%
1 month+12.64%
3 months+34.09%
6 months+16.32%
Current year+18.38%
1 week 2,921.2
Extreme 2921.2
3,075
1 month 2,576.1
Extreme 2576.1
3,120.7
Current year 2,088.1
Extreme 2088.1
3,120.7
1 year 2,088.1
Extreme 2088.1
3,120.7
3 years 1,385.05
Extreme 1385.05
3,515.7
5 years 1,227
Extreme 1227
3,515.7
10 years 962.65
Extreme 962.65
3,515.7
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2022
Director of Finance/CFO - 01/04/2026
Chief Tech/Sci/R&D Officer - 08/07/2024
Director TitleAgeSince
Chairman 73 01/04/2019
Director/Board Member 59 18/05/2020
Director/Board Member 67 16/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-2.27% - - 529.67Cr
-2.21%-3.11%+52.16%+91.64% 1,02400Cr
-2.22%-0.76%+51.08%+67.61% 66TCr
-2.99%-4.31%+18.59%+66.94% 45TCr
-0.88%+0.86%+29.77%+36.54% 35TCr
-10.89%-14.63%+9.27%+26.87% 29TCr
-1.38%-0.72%-0.79%+9.50% 25TCr
-10.08%-10.26%+40.32%+51.55% 24TCr
-2.32%-0.65%-15.84%-56.91% 21TCr
-2.88%-2.19%+26.54%+92.95% 19TCr
Average -3.35%+0.01%+23.46%+42.97% 40.75TCr
Weighted average by Cap. -2.42%-1.04%+32.70%+57.27%

Financials

2027 *2028 *
Net sales 4.26TCr 45Cr 39Cr 36Cr 33Cr 62Cr 62Cr 430.34Cr 166.5Cr 2.18TCr 168.61Cr 164.93Cr 6.92TCr 4.72TCr 50Cr 43Cr 40Cr 37Cr 69Cr 69Cr 477.58Cr 184.77Cr 2.41TCr 187.12Cr 183.03Cr 7.68TCr
Net income 1.17TCr 12Cr 11Cr 9.94Cr 9.07Cr 17Cr 17Cr 117.82Cr 46Cr 595.68Cr 46Cr 45Cr 1.9TCr 1.34TCr 14Cr 12Cr 11Cr 10Cr 19Cr 20Cr 135.65Cr 52Cr 685.83Cr 53Cr 52Cr 2.18TCr
Net Debt - -
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
08/26/08 ₹2,928.20 -1.00% 50,684
07/26/07 ₹2,957.80 -0.01% 1,55,659
04/26/04 ₹2,958.10 +0.70% 48,109
03/26/03 ₹2,937.50 -0.42% 56,012
02/26/02 ₹2,949.90 -1.54% 59,227
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,928.70INR
Average target price
3,081.00INR
Spread / Average Target
+5.20%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!